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4 MeV and 12 MeV (20%, 14% and 6% cases respectively) were 
used. In 54% cases applicator size was 5 cm in diameter. The 
smallest was 4 cm (15%) and the largest 7 cm (used only in 5% 
cases). Treatment applicators with 0°, 15° and 30° beveled 
tips were used (32%, 41% and 26% cases respectively). In 60% 
cases no bolus was needed; 0.5 cm bolus was used in 44 cases 
(29%). In all treatment procedures aluminium-lead shielding 
plates were used, 85% of which were 0.5 cm thick. The mean 
thickness of irradiated breast gland was 2.1 cm between 0.8 
cm and 3 cm. PTV volume (volume of tissue encompassed by 
the 90% isodose line) was rather small, with average volume 
of 42.50 cc ranging from 15.00 cc to 92.10 cc. 
Conclusions: Intraoperative radiotherapy is proved to be 
effective, tolerable and perspective treatment procedure. 
The external beam course afterwards was shortened by 1 
week.  
 
OC-0478   
7 years follow-up among patients with early stage breast 
cancer treated with single fraction IORT 
K. Horst1, F. Dirbas2, C. Fasola1, D. Goffinet1, B. Daniel3, D. 
Ikeda3 
1Stanford Cancer Center, Radiation Oncology, Stanford, USA  
2Stanford Cancer Center, Breast Cancer CCP, Stanford, USA  
3Stanford Cancer Center, Radiology, Stanford, USA  
 
Purpose/Objective: Long term follow-up (f/u) of patients 
(pts) undergoing accelerated partial breast irradiation (APBI) 
with single-fraction (SF) intraoperative radiotherapy (IORT) 
following breast conserving (BC) surgery is limited. We report 
our institutional experience with SF IORT in early stage 
breast cancer with respect to local control and toxicity.  
Materials and Methods: Records were reviewed for 64 
consecutive pts who received SF IORT from 2002 to 2014 at 
our institution. Of these, 47 pts were prospectively enrolled 
in an institutional IRB-approved phase I-II study between 2002 
and 2008. Eligible pts were ≥40 years with stage 0, I or II 
breast cancer measuring ≤2.5 cm without nodal involvement 
and were all screened with breast MRI for multifocal (MF) or 
multicentric (MC) disease (both exclusion criteria) (EC). 8 of 
the 47 pts did not fully meet eligibility criteria and declined 
additional surgery or radiation. The remaining 17 patients 
were treated per protocol guidelines between 2009 and 2014. 
IORT was delivered using either a 200 kV orthovoltage source 
or electrons to 15-21 Gy prescribed to the 90% isodose line. 
Results: The median age at treatment was 61 years (range: 
40-84 years). Median f/u time was 88 months (range 1 – 144 
months). Two pts had an ipsilateral breast tumor recurrence 
(IBTR), with one not meeting EC. A third patient with EIC and 
nodal micrometastasis later developed an axillary 
recurrence. All 3 patients had declined further surgery, 
radiation and/or systemic therapy. Overall, 52 of 64 pts (81%) 
received adjuvant systemic therapy consisting of endocrine 
therapy (n=49), chemotherapy (n=5) and/or trastuzumab 
(n=1). For patients who met original protocol guidelines, the 
IBTR rate was 1.6% at 6 years of f/u. On univariate analysis, 
the following factors emerged as significant predictors of 
IBTR: age <50 years (p<0.001), pathologic nodal involvement 
(p<0.001) and lack of any adjuvant systemic therapy 
(p=0.001). There were 2 cases of isolated distant relapses, 
which occurred in patients who had also declined adjuvant 
systemic therapy. Lack of systemic therapy was the only 
significant predictor of distant relapse (p=0.01). All 64 
patients tolerated IORT well with no evidence of grade III or 
higher toxicity. 
Conclusions: APBI using IORT is an inherently desirable 
option for BC therapy in appropriately selected pts. Our 
group has an IBTR rate of 1.6% at 7 years of f/u. We conclude 
that adherence to appropriate clinical guidelines for patient 
selection and strongly advising adherence to 
recommendations for additional surgery, radiation and 
systemic therapy are critical for successful use of APBI using 
SF IORT.  
   
 
Poster Discussion: IORT in breast cancer: Where do we 
stand?  
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Purpose/Objective: In selected patients, partial breast 
irradiation (PBI) could be a good option for delivering 
radiation therapy. Brachytherapy, conformal external 
radiation therapy (EBRT) and intraoperative radiation therapy 
(IORT) are the most common therapies as PBI. Using an 
Intrabeam® device as IORT has been considered expensive 
due to the initial cost of the equipment. 
The purpose of this study is to elucidate the real cost of IORT 
with Intrabeam® in breast cancer, comparing with 
conventional EBRT. 
Materials and Methods: Between Jan-2013 and Nov-2014, 75 
breast cancer patients were treated with IORT during 
conserving surgery in our institution, delivering a dose of 20 
Gy, with treating times adjusted to applicator diameter. 
Costs were estimated with time of surgery theatre 
occupation, radiation oncologist, physicist and technician, 
fungible material, applicators and total equipment cost 
distributed proportionately among patients. For EBRT costs 
calculations, there has been included institutional fares and 
price for distance travelled by patients daily. Also we 
calculated the waiting time that could influence QoL. 
Results: - For the 75 IORT patients, treatment time was 
registered by the device software, with an average of 
24.66min (15.97-49.07min), meaning an added cost of 
327.46€ (212.04-651.6€). Equipment total cost proportion 
was 1600 €/patient. Adding staff time and fungibles, the 
average total cost of the procedure has been 2398.45€ 
(2283.03-2722.6€). For the whole series, the total estimated 
cost has been 201123.75€. 
- The average 75 EBRT cost per patient was 3980.43€, with a 
total cost of 298532.25€ for the 75 patients. Considering daily 
patient routes twice a day, 25 days, total cost will be 
increased to 299376.45€, being a more realistic approach. 
- For the 75 patients treated with Intrabeam®, 98252.70€ 
have been saved, comparing with equivalent EBRT.  
Investigating daily waiting time during EBRT, we have 
compared the difference between the daily treatment 
appointment time and the real treatment time in 12 random 
patients of the previous year. We found an average daily 
delay of 15.9min/patient, that means a total waste of 6h and 
37min/patient for the whole treatment and a total of 497h 
for the 75 patients. As personal cost, the whole group had 
employed more than 20 days waiting to be treated with 
EBRT. 
Conclusions: Despite of the apparent high cost of equipment 
needed, IORT with an Intrabeam® device presents an 
